Rationale for Long-acting Growth Hormone Therapy and Future Aspects

Area of Science:

• Pediatric Endocrinology
• Pharmacology
• Biotechnology

Background:

• Recombinant human growth hormone (GH) is typically administered via daily subcutaneous injections.
• Daily GH treatment presents significant adherence challenges for pediatric patients and their caregivers.
• Poor adherence can lead to inadequate growth response, potentially affecting treatment continuation and reimbursement.

Purpose of the Study:

• To evaluate the efficacy and safety of novel long-acting growth hormone (LAGH) formulations.
• To assess the potential of LAGH to improve patient convenience and treatment adherence.
• To compare the growth outcomes of LAGH with daily GH administration.

Main Methods:

• Review of randomized clinical trials comparing LAGH formulations with daily GH.
• Analysis of data on growth velocity, body composition, and adverse events.
• Assessment of patient-reported convenience and adherence metrics.

Main Results:

• LAGH formulations demonstrate comparable efficacy to daily GH in restoring growth velocity and improving body composition.
• LAGH administration, due to less frequent dosing, enhances patient and caregiver convenience.
• No unexpected adverse effects were reported with LAGH formulations in clinical trials.

Conclusions:

• Long-acting growth hormone (LAGH) formulations offer an effective and safe alternative to daily GH injections.
• LAGH can significantly improve treatment adherence and patient convenience in pediatric growth disorders.
• These novel formulations may ensure sustained therapeutic benefits and support continued reimbursement for treatment.